Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CELGENE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 05:49pm EST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Celgene Corporation (“Celgene”) (NasdaqGS: CELG) to Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Celgene will receive only $50.00 in cash and 1.0 shares of Bristol-Myers for each share of Celgene that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-celg/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
02/20BRISTOL MYERS SQUIBB : Investor Starboard Unhappy With Bristol-Myers' Deal to Bu..
DJ
02/20BRISTOL MYERS SQUIBB : Myers says Starboard nominated five directors, bought sha..
RE
02/20BRISTOL MYERS SQUIBB : Myers Sees EPS, Revenue Growth Through 2025 from Celgene ..
DJ
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/11CELGENE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
02/05LYFEBULB : and Celgene Announce Call for Innovation Challenge Applications to Ad..
PR
02/04DEAL FILING : BMS added CVR late in Celgene negotiations
AQ
01/31CELGENE : Beats Profit Forecast As It Prepares For Takeover
DJ
01/31CELGENE : 4Q Earnings Snapshot
AQ
01/31CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
More news
Financials ($)
Sales 2019 17 124 M
EBIT 2019 9 859 M
Net income 2019 6 153 M
Debt 2019 8 347 M
Yield 2019 -
P/E ratio 2019 10,31
P/E ratio 2020 8,77
EV / Sales 2019 4,18x
EV / Sales 2020 3,46x
Capitalization 63 212 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 98,4 $
Spread / Average Target 8,8%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION41.50%63 212
JOHNSON & JOHNSON5.15%365 688
PFIZER-2.41%244 760
ROCHE HOLDING LTD.13.68%237 660
NOVARTIS7.90%231 060
MERCK AND COMPANY3.95%206 548